TNXP - Tonix Pharmaceuticals Announces Presentation at the 2024 BIO International Convention | Benzinga
Presentation to highlight statistically significant Phase 3 results of Tonmya™ for the management of fibromyalgia
New Drug Application (NDA) submission to the FDA on track for the second half of 2024
CHATHAM, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Jessica Morris, Chief Operating Officer, will present at the 2024 BIO International Convention being held June 3-6, 2024 in San Diego, Calif. The presentation will take place on Tuesday, June 4, 2024 at 10:45 a.m. PT in Theater 1 at the San Diego Convention Center.
To schedule a meeting with the Company's management at the convention, please submit a meeting request through the BIO One-on-One Partnering™ system or contact brandon.weiner@westwicke.com.
Tonix Pharmaceuticals Holding Corp.*
Tonix is a fully-integrated biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. Tonix's priority is to submit a New Drug Application (NDA) to the FDA in the second half of 2024 for Tonmya1, a product candidate for which two statistically significant Phase 3 studies have been completed for the management of fibromyalgia. TNX-102 SL is also ...